Algorae Pharmaceuticals (ASX:1AI) Days Payable: 0.00 (As of Dec. 2025)


What is Algorae Pharmaceuticals Days Payable?

Algorae Pharmaceuticals ASX:1AI +10.00% Days Payable is 0.00 as of Dec. 2025. The stock has 2 warning signs investors should review. Among 708 Biotechnology companies, Algorae Pharmaceuticals ranks worse than 141242.8% on this metric.

Algorae Pharmaceuticals's average Accounts Payable for the six months ended in Dec. 2025 was A$0.08 Mil. Algorae Pharmaceuticals's Cost of Goods Sold for the six months ended in Dec. 2025 was A$0.00 Mil.

The historical rank and industry rank for Algorae Pharmaceuticals's Days Payable or its related term are showing as below:

During the past 13 years, Algorae Pharmaceuticals's highest Days Payable was 529.25. The lowest was 529.25. And the median was 529.25.

ASX:1AI's Days Payable is not ranked *
in the Biotechnology industry.
Industry Median: 113.56
* Ranked among companies with meaningful Days Payable only.

Algorae Pharmaceuticals's Days Payable stayed the same from Dec. 2024 (0.00) to Dec. 2025 (0.00).

Algorae Pharmaceuticals Days Payable Historical Data

* Premium members only.

The historical data trend for Algorae Pharmaceuticals's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Algorae Pharmaceuticals Days Payable Chart

Algorae Pharmaceuticals Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Days Payable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Algorae Pharmaceuticals Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Days Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

ASX:1AI vs VRTX, REGN, ALNY: Days Payable Comparison

For the Biotechnology subindustry, Algorae Pharmaceuticals's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Algorae Pharmaceuticals Days Payable vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Algorae Pharmaceuticals's Days Payable distribution charts can be found below:

* The bar in red indicates where Algorae Pharmaceuticals's Days Payable falls into.


Algorae Pharmaceuticals Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

Algorae Pharmaceuticals's Days Payable for the fiscal year that ended in Jun. 2025 is calculated as

Days Payable (A: Jun. 2025 )
=Average Accounts Payable /Cost of Goods Sold*Days in Period
=( (Accounts Payable (A: Jun. 2024 ) + Accounts Payable (A: Jun. 2025 )) / count ) / Cost of Goods Sold (A: Jun. 2025 )*Days in Period
=( (0.117 + 0.069) / 2 ) / 0*365
=0.093 / 0*365
=N/A

Algorae Pharmaceuticals's Days Payable for the quarter that ended in Dec. 2025 is calculated as:

Days Payable (Q: Dec. 2025 )
=Average Accounts Payable / Cost of Goods Sold*Days in Period
=( (Accounts Payable (Q: Jun. 2025 ) + Accounts Payable (Q: Dec. 2025 )) / count ) / Cost of Goods Sold (Q: Dec. 2025 )*Days in Period
=( (0.069 + 0.081) / 2 ) / 0*365 / 2
=0.075 / 0*365 / 2
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Days Payable →
What does a Days Payable of 0.00 mean?
Algorae Pharmaceuticals (ASX:1AI) has a Days Payable of 0.00 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Algorae Pharmaceuticals and its competitors. Over the past decade, Algorae Pharmaceuticals' Days Payable has ranged from 529.25 to 529.25. According to the industry distribution chart, Algorae Pharmaceuticals ranks #999999 out of 708 companies in the Biotechnology industry.
Is Algorae Pharmaceuticals' Days Payable too high?
Algorae Pharmaceuticals' current Days Payable is 0.00. Over the past 10 years, this metric has ranged from a low of 529.25 to a high of 529.25. Based on the distribution chart, Algorae Pharmaceuticals ranks #999999 out of 708 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Algorae Pharmaceuticals' Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Algorae Pharmaceuticals ranks #999999 out of 708 companies for Days Payable. This places Algorae Pharmaceuticals in the lower half of its industry. The industry median Days Payable is 113.56. Historically, Algorae Pharmaceuticals' own Days Payable has ranged from 529.25 to 529.25 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.56, based on 708 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Algorae Pharmaceuticals and its competitors. For the Biotechnology industry, the median Days Payable is 113.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Algorae Pharmaceuticals's current Days Payable is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Algorae Pharmaceuticals stock overvalued right now?
Algorae Pharmaceuticals (ASX:1AI) has a current Days Payable of 0.00. The current Days Payable is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Algorae Pharmaceuticals (ASX:1AI), the current Days Payable is 0.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Algorae Pharmaceuticals Business Description

Other Exchanges LVCLF:USALHI0:Germany
Address 525 Collins Street, Level 23, Rialto South Tower, Melbourne, VIC, AUS, 3000
Algorae Pharmaceuticals Ltd is a clinical-stage pharmaceutical company developing transformative solutions for under met medical needs in the community. The firm develops AlgoraeOS, a closed-loop platform, leveraging computational tools to generate novel insights in silico that are being developed to initiate or accelerate therapeutic programs. The products of the company comprise AI-116, a novel combination drug candidate of cannabidiol (CBD) and an off-patent pharmaceutical ingredient. The company is conceptualized to be a potential treatment for dementia, including Alzheimer's disease, NTCELL is an alginate-coated capsule containing clusters of neonatal porcine choroid plexus cells. It also offers LP-003 Anti-obesity Drug and LC-002 migraine treatment.